Crinetics Tests Paltusotine for Carcinoid Syndrome
The Phase 3 trial launched in November 2025 to evaluate the daily oral drug for patients with the rare condition.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies prioritize patient quality of life when developing new treatments?
As of November 2025, Crinetics Pharmaceuticals has begun testing the drug paltusotine in a Phase 3 clinical trial for carcinoid syndrome. The study aims to determine the efficacy of the daily pill in reducing the frequency of flushing episodes.
Why it matters
Carcinoid syndrome occurs when neuroendocrine tumors that have spread to the liver release excess substances into the bloodstream. Finding effective oral treatments is critical as many current options require injectable somatostatin analogs every four weeks.
The study measures outcomes for 141 participants receiving an 80-milligram daily dose of paltusotine against a placebo group. Researchers are evaluating the reduction in daily flushing episodes over a 12-week primary treatment period.
The players
Crinetics Pharmaceuticals
This biotechnology company focuses on developing novel therapeutics for endocrine diseases and neuroendocrine tumors.
The details
The trial is assessing whether paltusotine, currently approved as Palsonify for acromegaly, can better manage symptoms caused by the circulation of 40 different substances. While standard treatments like octreotide and lanreotide help 80% of patients, this trial seeks to provide a daily oral alternative for those suffering from flushing, which affects over 90% of cases.
Timeline
November 2025: The CAREFNDR trial randomized its first patient.
2025 and 2026: The window for ongoing patient enrollment.
October 15, 2026: An image report of the syndrome appeared in the New England Journal of Medicine.
Health Landscape
This trial follows a pattern set by the approval of telotristat ethyl for carcinoid syndrome-associated diarrhea by expanding the range of oral pharmacotherapy for neuroendocrine tumor patients. It shifts the standard of care from strictly injectable somatostatin analogs toward more convenient daily pills.
Patients currently managing carcinoid syndrome via injections every four weeks may gain a more convenient daily treatment option if the trial succeeds. This development could eventually reduce the reliance on frequent clinic visits for standard somatostatin analog administration.
The takeaway
Carcinoid syndrome remains a complex condition where tumor-derived substances cause systemic symptoms like flushing and heart disease. Future treatments aim to improve daily quality of life by transitioning patients toward effective oral medication regimens.
Further reading
For more information on current treatment standards and ongoing research, visit the Cancer section.
More information
View the clinical trial study listing for specific patient inclusion criteria and updates.
Source note: This article includes information reported by Medical Daily.
Live Poll
Do you trust that pharmaceutical companies prioritize patient quality of life when developing new treatments?
